NEW YORK (GenomeWeb News) – PerkinElmer this week announced the establishment of direct operations in Israel, headquartered near Tel Aviv. Through its new Israel base, PerkinElmer will commercialize and support its life sciences and technologies, analytical sciences, and laboratory services business offerings.

The company's board separately last week declared a quarterly dividend of $.07 per share, payable on Nov. 8 to shareholders of record at the close of business on Oct. 18.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.